Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome from Non-Controlling InterestsIncome towards Parent CompanyInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeNon Operating Investment IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

ImmunityBio (IBRX) Equity Income (2021 - 2023)

ImmunityBio (IBRX) has disclosed Equity Income for 3 consecutive years, with -$1.3 million as the latest value for Q3 2023.

  • Quarterly Equity Income rose 71.84% to -$1.3 million in Q3 2023 from the year-ago period, while the trailing twelve-month figure was -$1.3 million through Jun 2024, up 91.23% year-over-year, with the annual reading at -$7.5 million for FY2023, 37.65% up from the prior year.
  • Equity Income for Q3 2023 was -$1.3 million at ImmunityBio, up from -$4.0 million in the prior quarter.
  • The five-year high for Equity Income was -$197000.0 in Q1 2022, with the low at -$4.5 million in Q3 2022.
  • Average Equity Income over 3 years is -$2.6 million, with a median of -$2.9 million recorded in 2022.
  • Peak annual rise in Equity Income hit 71.84% in 2023, while the deepest fall reached 1086.29% in 2023.
  • Over 3 years, Equity Income stood at -$803000.0 in 2021, then tumbled by 342.59% to -$3.6 million in 2022, then surged by 64.69% to -$1.3 million in 2023.
  • According to Business Quant data, Equity Income over the past three periods came in at -$1.3 million, -$4.0 million, and -$2.3 million for Q3 2023, Q2 2023, and Q1 2023 respectively.